Executive Summary
ReGen Therapeutics Plc's strategy is to develop a pharmaceutical preparation, based on the peptides contained within the Colostrinin??? complex, which has already shown efficacy when tested on human subjects suffering from Alzheimer's disease. The results of research announced in April 2005 have indicated that Colostrinin??? and one of its constituent peptides may also have applications in the treatment of Parkinson's disease. A nutraceutical version of Colostrinin??? for use in the early stages of cognitive decline, a product primarily targeted at humans, is in an advanced stage of development. Discussions with potential development partners are ongoing. We are also some way forward in developing Colostrinin??? as a veterinary nutraceutical for companion animals. In October 2004 ReGen acquired Guildford Clinical Pharmacology Unit Ltd, a Contract Research Organisation based in Surrey, England. The key features of its business are innovation in measuring pain and motility of the gastrointestinal system, its hospital site and an international list of clients.
Company History
Current Events
Business Model
Products/Services
Segments/Customers
Production/Operations
Distribution/Routes to Market
Market & Competition
Market Share
Main Competitors
Competitive Strengths and Weaknesses
Management
Financials
Profit & Loss
Balance sheet
Cashflow
Valuation
Comparable Companies
SWOT Analysis
Strengths
Weaknesses
Opportunities
Threats
